Even though two CETP inhibitors failed to translate increases in HDL cholesterol into improved cardiovascular outcomes, Dezima Pharma B.V. and Forbion Capital Partners are betting DEZ-001 will improve outcomes based on large reductions in LDL cholesterol and lipoprotein(a).

Last week, newco Dezima licensed exclusive, worldwide rights to DEZ-001 from Mitsubishi Tanabe Pharma Corp. for an undisclosed upfront payment and a portion of profits from commercialization. The deal excludes some Asian territories.